Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Xtandi Filed for Hormone-Sensitive Prostate Cancer in Japan
July 31, 2019
- Over 1,000 GSK Staffers Worked from Home amid Govt’s Telework Campaign
July 30, 2019
- NEC Snaps Up Norway’s Bioinformatics Firm
July 30, 2019
- Sumitomo Dainippon Ekes Out Quarterly Growth as North America Sales Offset Japan Dip
July 30, 2019
- Shionogi’s Q1 Sales Sag 10.5% after Hefty Xofluza Milestone Gain
July 30, 2019
- Mitsubishi Tanabe’s Sales Fall 6.9% as Gilenya Snafu Takes Toll
July 30, 2019
- Lonsurf Gets EU Nod for Gastric Cancer: Taiho
July 30, 2019
- Nesp Biosame to Hit Japan Shelves on August 5
July 29, 2019
- Bayer Files Eylea for Neovascular Glaucoma
July 29, 2019
- Takeda, Meiji to End Copromotion for Rozerem
July 29, 2019
- Pfizer, Takeda Wind Up Enbrel Copromotion
July 29, 2019
- Chugai Nets 40%-Plus Profit Rise, but Keeps 3-Year EPS Target; President Nixes Avastin Biosame
July 26, 2019
- Opdivo Posts Mixed Results in 1st-Line NSCLC, Scores Win in I/O-I/O Combo
July 26, 2019
- Sumitomo Dainippon to Invest in US Blood Sample Device Startup
July 26, 2019
- EMA Accepts Xtandi for Review in Hormone-Sensitive Prostate Cancer
July 25, 2019
- Novo Files Oral Semaglutide in Japan
July 25, 2019
- Ayumi to Ease Restrictions on Enbrel Biosimilar Use as Product Boost Progresses
July 24, 2019
- HIF-PH Inhibitor Vadadustat Submitted in Japan: Mitsubishi Tanabe
July 24, 2019
- Lenvima/Keytruda Gets FDA’s Breakthrough Status for HCC
July 24, 2019
- Dissolving JV with Takeda, PRA Launches Independent CRO Biz in Japan
July 24, 2019
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…